BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19319108)

  • 1. [Bevacizumab and non-small cell lung cancer: a new step?].
    Pérol M; Arpin D
    Rev Mal Respir; 2009 Feb; 26(2):125-38. PubMed ID: 19319108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis and lung cancer].
    Pérol M; Arpin D
    Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    Herbst RS; Sandler AB
    Oncologist; 2004; 9 Suppl 1():19-26. PubMed ID: 15178812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC; Socinski MA
    Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
    Wagstaff AJ; Keam SJ; McCormack PL
    BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeted therapies in the treatment of non-small cell lung cancer].
    De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
    Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab as first-line treatment for advanced non-small cell lung cancer.
    Socinski MA
    Drugs Today (Barc); 2008 Apr; 44(4):293-301. PubMed ID: 18536787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C
    Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.
    Yano S; Matsumori Y; Ikuta K; Ogino H; Doljinsuren T; Sone S
    Int J Clin Oncol; 2006 Apr; 11(2):73-81. PubMed ID: 16622742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.